Cryoport Systems’ Temperature-Controlled Supply Chain Blog
Learn more from our expert leaders on the latest industry trends, global news, and company updates.
Managing the Cold Chain
04/21/2026
Validate Cryopreservation as a Defined Input, not a Variable
Most early‑stage cell therapy programs continue to rely on fresh starting material, particularly in pre‑clinical and Phase I development. That reliance is often driven by habit rather than data. Fresh workflows are familiar, but they also embed variability into the earliest experiments, where reproducibility is hardest to restore later. As development pressure increases, teams begin looking for ways to stabilize inputs without introducing new unknowns.
Managing the Cold Chain
04/21/2026
Accelerate Your Trials Without Losing Control With an End-to-End Supply Chain Model
As programs shift from Phase I to Phase II, the workload starts to overlap in new ways. Sample volumes increase as more sites operate in parallel, and activities that once occurred in sequence now run at the same time. The work itself is largely the same, but keeping it coordinated requires more time and attention.
Industry Insights
04/14/2026
Building Global Readiness: Key Takeaways from Matthew Frazzetta at Hope Is Not a Workflow
As cell and gene therapies continue to advance scientifically, operational readiness is increasingly determining whether those therapies reach patients at scale. During a presentation at Hope Is Not a Workflow, Matthew Frazzetta, Vice President of Global Accounts for BioServices at Cryoport Systems, addressed a question that is becoming impossible for the industry to ignore: How do we build a global, standardized, and scalable supply chain capable of supporting the next generation of advanced therapies?
Industry Insights
04/13/2026
What Will It Take to Move Cell Therapy Forward? Reflections from the Hope Is Not a Workflow Panel
At the recent Hope Is Not a Workflow event, industry leaders came together to tackle some of the most persistent questions facing cell and gene therapy today. During a panel, Dominic Clarke (VP, IntegriCell® Technical Operations, Cryoport Systems) joined the discussion to share his perspective on what is slowing adoption and what it will take to move the industry forward in a meaningful way.
Managing the Cold Chain
04/09/2026
Where Innovation Is Moving the Advanced Therapies Supply Chain: A Q&A with Alison Pritchard
Following the Advanced Therapies Congress 2026, where Alison Pritchard delivered a keynote and participated in a panel discussion, she sat down for a brief conversation to expand on some of the themes that emerged during this year’s event. Alison’s perspective captures a few of the ideas she believes are shaping the next phase of supply chain design in advanced therapies.
Industry Insights
03/19/2026
ATC 2026 Panel Recap: Harnessing Technological Innovation to Optimize Supply Chain and Logistics in Advanced Therapies
Advanced Therapies Congress 2026 hosted a panel discussion, Harnessing Technological Innovation to Optimize Supply Chain and Logistics in Advanced Therapies, that centered on a reality the field continues to confront... while the desire for digital acceleration is strong, the industry’s underlying infrastructure is not yet positioned to fully benefit from it. Alison Pritchard, VP Business Development, joined fellow panelists to examine where technology can make a meaningful impact today and where foundational alignment must come first.
Industry Insights
03/19/2026
ATC 2026 Keynote Recap: Building Global Readiness for Advanced Therapies
Alison Pritchard, VP of Business Development – EMEA at Cryoport Systems, delivered the Keynote Address at the Advanced Therapies Congress 2026, grounding the discussion in the accelerating pace of global expansion across the cell and gene therapy industry. Clinical trials now commonly stretch across regions, and manufacturing networks are distributed in ways that require constant coordination. These patterns have become the norm rather than the exception. As she described it, the operating environment for advanced therapies has already become global, and every program is expected to function within that reality much earlier than in the past.
Managing the Cold Chain
03/19/2026
Advance Program Stability by Building Cryopreservation Into the System, Not Around It
Cryopreservation has become a practical way for early programs to give themselves more room to plan, especially when collection schedules don’t line up neatly with manufacturing availability. How the material actually enters the frozen state, though, has a noticeable influence on what teams see later in development. When sites follow their own methods or adapt the process to local routines, those differences show up in the frozen material and stay with it.
Managing the Cold Chain
03/18/2026
The Slow Drift Toward Variability and the Case for Standardization
Teams in mid-phase development often look back at their operational processes and see that they carry the imprint of every decision made along the way. No single choice felt significant in the moment, and each helped to keep the program moving. But as more sites are added and new regions open, the one-off decisions made along the way become part of a broader system that begins to show its unevenness variability as the program expands.Categories
- All (63)
- Industry Insights (24)
- Managing the Cold Chain (55)
- Navigating Logistics (27)
- Patient Access and Awareness (8)
Topics
- Asia
- ATMPs
- Biologics
- BioServices
- Biostorage
- CDMO
- CDMOs
- Cell Therapy
- Clinical Trials
- Cold Chain Management
- Commercialization
- CROs
- Cryopreservation
- Europe
- Fragmentation
- Gene Therapy
- Global Logistics Tracking
- Global Supply Chain Management
- International Shipping
- North America
- Risk Mitigation
- Standards and Compliance
- Supply Chain Management